Bioxcell Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Satisfied Charges ₹ 0.50 M
as on 06-07-2024
- Revenue 39.38%
(FY 2020)
- Profit 23.53%
(FY 2020)
- Ebitda 5.50%
(FY 2020)
- Net Worth 22.02%
(FY 2020)
- Total Assets 26.84%
(FY 2020)
About Bioxcell Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Raj Satyam and Parimala Satyam serve as directors at the Company.
- CIN/LLPIN
U24232TG2012PTC082262
- Company No.
082262
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2012
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bioxcell Life Sciences Private Limited offer?
Bioxcell Life Sciences Private Limited offers a wide range of products and services, including Wash Basins, Sanitaryware & Fittings, Urinals, Bird Food, Poultry & Animal Food, Animal Feed Supplement, Fertilizers and Soil Additives, Bio Fertilizers.
Who are the key members and board of directors at Bioxcell Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Satyam  | Director | 31-Jul-2012 | Current |
| Parimala Satyam | Director | 31-Jul-2012 | Current |
Financial Performance of Bioxcell Life Sciences.
Bioxcell Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 39.38% increase. The company also saw a substantial improvement in profitability, with a 23.53% increase in profit. The company's net worth Soared by an impressive increase of 22.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioxcell Life Sciences?
In 2020, Bioxcell Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Corporation Bank Creation Date: 31 Dec 2015 | ₹0.50 M | Satisfied |
How Many Employees Work at Bioxcell Life Sciences?
Unlock and access historical data on people associated with Bioxcell Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioxcell Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioxcell Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
